{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'SAE', 'Serious Adverse Event', 'SGOT', 'Serum Glutamic Oxaloacetic Transaminase', 'SGPT', 'Serum Glutamic-Pyruvic Transaminase', 'SGRQ-C', \"St. George's Respiratory Questionnaire for COPD patients\", 'SMQ', 'Standardised MedDRA Query', 'SoA', 'Schedule of Activities', 'SRM', 'Study Reference Manual', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'TIO', 'Tiotropium', 'TQT', 'Thorough QT', 'UK', 'United Kingdom', 'ULN', 'Upper Limit of Normal', 'UMEC', 'Umeclidinium', 'US', 'United States', 'VI', 'Vilanterol', 'WBC', 'White Blood Cell', 'WOCBP', 'Woman of child-bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'ELLIPTA', 'Respimat', 'Spiriva Handihaler', '80']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.2.', 'Appendix 2: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the Investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study Participantss.', 'The Investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 Code of Federal Regulations (CFR), ICH guidelines,', 'the IRB/IEC, European regulation 536/2014 for clinical studies (if', 'applicable), and all other applicable local regulations', 'Financial Disclosure', 'Investigators and sub-Investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', '81']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study centre.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', \"A copy of the ICF(s) must be provided to the participant or the participant's\", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating Investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', '82']\n\n###\n\n", "completion": "END"}